Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Paterson, R W ^a   Bartlett, J W ^b   Blennow, K ^c   Fox, N C ^a   Shaw, L M ^d   Trojanowski, J Q ^d   Zetterberg, H ^a,c   Schott, J M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CD40 ANTIGEN; CHROMOGRANIN A; COLONY STIMULATING FACTOR 1; CYSTATIN C; GELATINASE A; INTESTINAL TREFOIL FACTOR; NOTCH RECEPTOR; PREGNANCY ASSOCIATED PROTEIN; TAU PROTEIN; THROMBOPLASTIN; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; VASCULOTROPIN; CST3 PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; PEPTIDE; TFF3 PROTEIN, HUMAN; AMYLOID; GROWTH FACTOR;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PROTEIN CEREBROSPINAL FLUID LEVEL; RECEIVER OPERATING CHARACTERISTIC; AMYLOIDOSIS; ATROPHY; BRAIN; BRAIN VENTRICLE; CEREBROSPINAL FLUID; MENTAL HEALTH; PATHOLOGY; STATISTICS; VERY ELDERLY; HIPPOCAMPAL ATROPHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOIDOSIS; APOLIPOPROTEIN E4; ATROPHY; BIOMARKERS; BRAIN; CEREBRAL VENTRICLES; CYSTATIN C; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MENTAL STATUS SCHEDULE; MILD COGNITIVE IMPAIRMENT; PEPTIDES; STATISTICS AS TOPIC; TAU PROTEINS;

EID: 84905254120     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.58     Document Type: Article

References (39)

1. Schott JM, Frost C, Whitwell JL, Macmanus DG, Boyes RG, Rossor MN et al. Combining short interval MRI in Alzheimer's disease: implications for therapeutic trials. J Neurol 2006; 253: 1147-1153. (Pubitemid 44511470)
2. Woo JI, Kim JH, Lee JH. Age of onset and brain atrophy in Alzheimer's disease. Int Psychogeriatr 1997; 9: 183-196. (Pubitemid 27455501)
3. Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 2003; 362: 1121-1122. (Pubitemid 37222338)
4. Barnes J, Carmichael OT, Leung KK, Schwarz C, Ridgway GR, Bartlett JW et al. Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiol Aging 2013; 34: 1996-2002.
5. Josephs KA, Whitwell JL, Knopman DS, Hu WT, Stroh DA, Baker M et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 2008; 70: 1850-1857. (Pubitemid 351653955)
6. Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC. Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol Aging 2010; 31: 1452-1462.
7. Fox NC, Scahill RI, Crum WR, Rossor MN. Correlation between rates of brain atrophy and cognitive decline in AD. Neurology 1999; 52: 1687-1689. (Pubitemid 29220648)
8. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144.
9. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234. (Pubitemid 43238346)
10. Mattsson N, Insel P, Nosheny R, Trojanowski JQ, Shaw LM, Jack CR Jr et al. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging 2014; 35: 614-622.
11. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
12. Kauwe J, Bailey M, Ridge P, Cruchaga C, Foutz S, Perry R et al. Association of genetic variants with cerebrospinal fluid protein levels of ACE, MMP3 and other proteins and risk for Alzheimer's disease. Alzheimers Dement 2013; 9: 677-678.
13. Mattsson N, Insel P, Nosheny R, Zetterberg H, Trojanowski JQ, Shaw LM et al. CSF protein biomarkers predicting longitudinal reduction of CSF beta-amyloid42 in cognitively healthy elders. Transl Psychiatry 2013; 3: e293.
14. Box GEP, Cox DR. An analysis of transformations. J Roy Stat Soc B 1964; 26: 211-252.
15. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685-691. (Pubitemid 351508080)
16. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997; 16: 623-629. (Pubitemid 127767641)
17. Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K et al. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage. 2010; 51: 1345-1359.
18. Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN, Fox NC. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology 2005; 65: 119-124. (Pubitemid 40967786)
19. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 1995; 45: 486-490.
20. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279-284. (Pubitemid 33000466)
21. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-216.
22. Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet 2004; 363: 392-394. (Pubitemid 38169550)
23. Jack CR Jr., Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004; 62: 591-600. (Pubitemid 38252801)
24. Andrews KA, Modat M, Macdonald KE, Yeatman T, Cardoso MJ, Leung KK et al. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PloS One 2013; 8: e58816.
25. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-367.
26. Whitwell JL, Petersen RC, Negash S, Weigand SD, Kantarci K, Ivnik RJ et al. Patterns of atrophy differ among specific subtypes of mild cognitive impairment. Arch Neurol 2007; 64: 1130-1138. (Pubitemid 47258072)
27. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-613. (Pubitemid 37162569)
28. Probst JC, Zetzsche T, Weber M, Theilemann P, Skutella T, Landgraf R et al. Human intestinal trefoil factor is expressed in human hypothalamus and pituitary: evidence for a novel neuropeptide. FASEB J 1996; 10: 1518-1523. (Pubitemid 26384448)
29. Hinz M, Schwegler H, Chwieralski CE, Laube G, Linke R, Pohle W et al. Trefoil factor family (TFF) expression in the mouse brain and pituitary: changes in the developing cerebellum. Peptides 2004; 25: 827-832. (Pubitemid 38721349)
30. Shi HS, Yin X, Song L, Guo QJ, Luo XH. Neuropeptide Trefoil factor 3 improves learning and retention of novel object recognition memory in mice. Behav Brain Res 2012; 227: 265-269.
31. Denton R, Meredith JE. Gamma secretase Notch biomarkers. US patent US 7,989,208; 2011.
32. Tong G, Wang JS, Sverdlov O, Huang SP, Slemmon R, Croop R et al. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral gamma-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin Ther 2012; 34: 654-667.
33. Kaur G, Levy E. Cystatin C in Alzheimer's disease. Front Mol Neurosci 2012; 5: 79.
34. Dutta G, Barber DS, Zhang P, Doperalski NJ, Liu B. Involvement of dopaminergic neuronal cystatin C in neuronal injury-induced microglial activation and neurotoxicity. J Neurochem 2012; 122: 752-763.
35. Religa P, Cao R, Religa D, Xue Y, Bogdanovic N, Westaway D et al. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci Rep 2013; 3: 2053.
36. McLarnon JG. Microglial chemotactic signaling factors in Alzheimer's disease. Am J Neurodegener Dis 2012; 1: 199-204.
37. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002; 23: 237-243. (Pubitemid 34137098)
38. Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 2012; 6: 455-476.
39. Blennow K, Davidsson P, Wallin A, Ekman R. Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease?. Dementia 1995; 6: 306-311.